Granisetron Hydrochloride Injection

This product is a highly selective 5-HT3 receptor antagonist, which has a good preventive and therapeutic effect on nausea and vomiting caused by radiotherapy, chemotherapy and surgery. Factors such as radiotherapy, chemotherapy and surgery can cause enterochromaffin cells to release 5-HT, which can activate the 5-HT3 receptors of the central nervous system or vagus nerve and cause vomiting reflex. The mechanism of this product to control nausea and vomiting is to antagonize the 5-HT3 receptors in the central chemoreceptor area and peripheral vagus nerve endings, thereby inhibiting the occurrence of nausea and vomiting. This product has high selectivity and no side effects such as extrapyramidal reactions and excessive sedation.

The main ingredient of this product is granisetron hydrochloride, and the excipients are sodium chloride and water for injection. Chemical name: 1-methyl-N-[bridge-9-methyl-9-azabicyclo(3.3.1)nonane-3-yl]-1H-indazole-3-carboxamide hydrochloride.

This product is a colorless clear liquid.

This product is used to prevent or treat nausea and vomiting caused by chemotherapy, and to prevent and treat postoperative nausea and vomiting

The adult dosage is usually 3 mg, diluted with 20-50 ml 5% glucose injection or 0.9% sodium chloride injection, and injected intravenously 30 minutes before treatment. The administration time should exceed 5 minutes. Most patients only need to take the drug once, and the prevention effect on nausea and vomiting can last for more than 24 hours. If necessary, the number of administrations can be increased by 1-2 times, but the maximum daily dose should not exceed 9 mg. The elderly and those with liver and kidney dysfunction do not need to adjust the dose.

Common adverse reactions include headache, fatigue, fever, constipation, and occasional transient asymptomatic elevation of liver transaminases. These reactions are mild and do not require special treatment.

It is contraindicated for those who are allergic to this product; it is contraindicated for those who have gastrointestinal obstruction.

1. Granisetron does not induce or inhibit the cytochrome P-450 drug metabolizing enzyme system; 2. Granisetron is metabolized by the hepatic cytochrome P-450 drug metabolizing enzyme. Inducing or inhibiting this enzyme can change the clearance rate and half-life of granisetron.

Keep away from light and store in a sealed container.

3ml:3mg

PKU HealthCare Corp., Ltd.

• Founded in:

  1993-05-18

• Address:

  No. 21, Fangzheng Avenue, Shuitu Town, Beibei District, Chongqing

• Tax NO.:

  91500000450533779H

• Registered Funds:

  595.987425 yuan

• Website:

  Log in to view

• Email:

  Log in to view